Green Drug Discovery: Leveraging Biodiversity for Sustainable Pharmaceutical Solutions

The pharmaceutical industry is undergoing a crucial transformation toward sustainability, driven by the urgent need to reduce environmental harm while maintaining innovation in drug discovery and development. Next-generation green pharma integrates biodiversity, green chemistry, biotechnology, and artificial intelligence (AI) to create more eco-friendly and efficient drug production processes. Nature remains a vast source of bioactive compounds, with plants, microbes, and marine organisms offering promising therapeutic potential. Advances in synthetic biology, CRISPR gene editing and metabolic engineering enable the sustainable synthesis of natural compounds, reducing reliance on resource-intensive extraction methods. In addition, green chemistry techniques, such as biocatalysis and supercritical fluid extraction, minimize hazardous waste and lower energy consumption. AI and machine learning accelerate drug discovery by efficiently identifying novel compounds, reducing the need for traditional, time-consuming experimental methods. However, the shift to sustainable pharma faces challenges, including ethical concerns over bioprospecting, conservation efforts, and fair benefit-sharing of biodiversity resources. As industries and policymakers increasingly focus on sustainability, the pharmaceutical sector is poised to embrace greener practices, ensuring both human health advancements and environmental protection. This paper explores the transformative potential of green pharmaceuticals and their role in shaping a sustainable future for medicine.